LDL Cholesterol

13 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

Cardiology

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for Hypercholesterolemia: Results From a Phase 1 Trial

By MedXY|May 15, 2026

Laroprovstat, an investigational oral PCSK9 inhibitor, was well tolerated and produced substantial LDL cholesterol reductions, especially when combined with rosuvastatin, supporting further development for hypercholesterolemia.

Diabetes & Endocrinology

LDL Cholesterol

Latest news

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for Hypercholesterolemia: Results From a Phase 1 Trial

Pediatric Type 1 Diabetes Care Still Misses LDL Targets Despite Clear Indications for Lipid-Lowering Therapy

PCSK9 Inhibition Lowers LDL Cholesterol in Heterozygous Familial Hypercholesterolemia Regardless of LDL Receptor Variant Function

Evolution and Future Frontiers of PCSK9 Inhibition: From Genetic Discovery to Genomic Medicine

Beyond Statins: The Evolution and Clinical Impact of PCSK9 Inhibition in Cardiovascular Risk Management

Why Universal Cholesterol Screening for Familial Hypercholesterolaemia Should Wait Until Age One

Genetic Insights into LDL Cholesterol and Coronary Artery Disease Risk Across Diverse Global Populations

Long-Term Stroke Risk in Healthy Women: The Predictive Role of hsCRP, LDL Cholesterol, and Lipoprotein(a)

Reevaluating Mortality Risks: The Paradox of Low Apolipoprotein B and LDL-Cholesterol Levels in Cardiovascular Health

Evolocumab and Saphenous Vein Graft Patency Post-CABG: Insights from the NEWTON-CABG Trial

Obicetrapib: A Promising Advance in LDL Cholesterol Lowering for High Cardiovascular Risk Patients

Berberine and Cinnamon Synergy: A Promising Adjunct Therapy for Improving Glycemic Control and LDL Cholesterol in Type 2 Diabetes

Evolocumab for Intensive LDL Cholesterol Reduction in Autoimmune and Inflammatory Disease Patients: Insights from the FOURIER Trial